From November 6-8, 2025, Mexico City hosted the XXVI International AMMVIH Symposium, an event that brought together national and international specialists to analyze advances, challenges, and new strategies in the comprehensive care of people living with HIV.
The event featured a program structured around clinical cases, specialized debates, therapeutic updates, and discussions on mental health, co-infections, and aging within the HIV population. Experts discussed new therapeutic opportunities, including injectable treatments, and emphasized the importance of collaboration between government, the pharmaceutical industry, academia, and civil society to curb the HIV epidemic.
Specialists also called for strengthening prevention, combating stigma, and ensuring access to innovative treatments. It was noted that sexual transmission remains the primary route, and late diagnosis continues to be a critical obstacle. A significant advancement announced was the incorporation of dolutegravir/lamivudine as a preferred regimen in the public sector for 2025-2026.
"This innovation allows for the optimization of public resources and, most importantly, significantly improves the quality of life for people living with the virus," stated Dr. Rangel. The event concluded with a lecture on HIV cure strategies and an inaugural dinner featuring the Mexico City Gay Men's Chorus, symbolizing the unity of science, community, and diversity.
